

NOVO NORDISK A S  
Form 6-K  
June 19, 2013

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**June 19, 2013**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## **Federal Circuit Court rules on patent litigation involving**

### **Prandin® (repaglinide)**

**Bagsværd, Denmark & Plainsboro, NJ 18 June 2013** –Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the treatment of type 2 diabetes was invalid. This decision favors approval and launch of a generic repaglinide product.

The Federal Circuit also reversed, with a unanimous 3-0 ruling, the District Court decision that Novo Nordisk had committed inequitable conduct during the time the company attempted to acquire the patent.

Novo Nordisk continues to believe in the validity of the patent and is reviewing the ruling. Novo Nordisk expects to provide an update on the case in connection with the announcement of the financial results for the first six months of 2013 on 8 August 2013.

Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed-dose repaglinide/metformin tablet under the trade name PrandiMet® in the US. In 2012, sales of Prandin® and PrandiMet® in the US amounted to 1.2 billion Danish kroner (approximately 200 million USD).

*Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its*

products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).

**Further information**

*Media:*

Mike Rulis	+45 3079 3573	<a href="mailto:mike@novonordisk.com">mike@novonordisk.com</a>
Ken Inchausti (US)	+1 609 240 2919	<a href="mailto:kiou@novonordisk.com">kiou@novonordisk.com</a>

*Investors:*

Kasper Roseeuw Poulsen	+45 4442 4303	<a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a>
Frank Daniel Mersebach	+45 4442 0604	<a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a>
Lars Borup Jacobsen	+45 3075 3479	<a href="mailto:lbpj@novonordisk.com">lbpj@novonordisk.com</a>
Jannick Lindegaard (US)	+1 609 786 4575	<a href="mailto:jlis@novonordisk.com">jlis@novonordisk.com</a>

**Novo Nordisk A/S**

Investor Relations

Novo Allé  
2880 Bagsværd  
Denmark

Telephone:

+45 4444 8888

Internet:

[www.novonordisk.com](http://www.novonordisk.com)

CVR no:

24 25 67 90

Company announcement No 45 / 2013

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 19, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer